Granted Patent
B2
US 12,282,014 · App. 15/777,428 · Granted Apr 22, 2025
Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
Assignee:
Dana-Farber Cancer Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods of screening for compounds that interfere with the interaction between ERG. ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins. Included are methods of screening for compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and BAF155. Methods of treating prostate cancer with compounds that interfere with the interaction between ERG, ETV1, ETV4 or ETV5 and mSWI/SNF (BAF) chromatin remodeling complex proteins are also provided.
Claims (14)
1. A method of identifying a compound that interferes with the physical interaction between an erythroblast transformation specific (ETS)-related gene (ERG) protein, and a mouse Switch/Sucrose Non-Fermentable (mSWI/SNF) (BRG1-associated factors (BAF)) chromatin remodeling complex protein, wherein
i) the ERG protein is ERG: ΔPNT domain (deletion of pointed domain), ERG: ΔETS domain (deletion of ETS domain), ERG: ΔCAD domain (deletion of C-terminal Activation domain), ERG-Δ225-271, ERG-Δ259-265, or ERG: R367K Mutant (R367K DNA Binding mutant) and
ii) the mSWI/SNF (BAF) chromatin remodeling complex protein is BAF155, the method comprising:
a) administering a candidate compound at a first concentration to a first set of one or more cells;
b) directly determining the strength of the protein-protein interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein in the first set of one or more cells using mass spectrometry;
c) administering the candidate compound at a second concentration to a second set of one or more cells;
d) directly determining the strength of the protein-protein interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein in the second set of one or more cells using mass spectrometry; and
e) comparing the strength of the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein of the first set of one or more cells to the strength of the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein of the second set of one or more cells,
wherein if the strength of the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein in the first set of one or more cells is weaker than the strength of the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein in the second set of one or more cells, then the candidate compound interferes with interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein.
2. The method of claim 1 , wherein the first and second sets of one or more cells are normal prostate cells, prostate cancer cells, normal prostate cell line cells, or prostate cancer cell line cells.
3. The method of claim 2 , wherein the first and second sets of one or more cells are vertebral-cancer of the prostate (VCaP) cells, prostate cancer-3 (PC-3) cells, prostate epithelial cells ectopically expressing simian virus 40 (SV40) large T antigen (LT), SV40 small T antigen (ST), telomerase reverse transcriptase (TERT), and androgen receptor (AR) (LHS-AR cells), LHS-AR cells ectopically expressing an ERG protein, or LHS-AR cells ectopically expressing an ETV1 protein.
4. The method of claim 1 , wherein the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein of the first set of one or more cells is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% weaker than the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein of the second set of one or more cells.
5. The method of claim 1 , wherein the determining the strength of the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein comprises stable isotope labeling by amino acids in cell culture (SILAC) mass spectrometry.
6. The method of claim 1 , wherein the determining the interaction between the ERG protein and the mSWI/SNF (BAF) chromatin remodeling complex protein further comprises measuring of expression of at least one prostate cancer pathway gene or protein selected from the group consisting of FLI1 (Friend leukemia integration 1 transcription factor), UBE2C (Ubiquitin-conjugating enzyme E2C), AR (androgen receptor), and EZH2 Enhancer of zeste homolog 2).
Assignments (2)
CONFIRMATORY LICENSE
Recorded Nov 13, 2019
From: DANA-FARBER CANCER INST
To: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 050997/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 18, 2018
From: KADOCH, CIGALL; SANDOVAL, GABRIEL; HAHN, WILLIAM C.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 046896/0664 →
Continuity (2)
Provisional Application
62257512
· Nov 19, 2015
References Cited (398)
US 3717642A
· Von Strandtmann
· 1973
[cited by applicant]
US 4109496A
· Allerman et al.
· 1978
[cited by applicant]
US 4650796A
· George et al.
· 1987
[cited by applicant]
US 4868103A
· Stavrianopoulos et al.
· 1989
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5225422A
· Nagata et al.
· 1993
[cited by applicant]
US 5283317A
· Saifer et al.
· 1994
[cited by applicant]
US 5631169A
· Lakowicz et al.
· 1997
[cited by applicant]
US 5677158A
· Zhou et al.
· 1997
[cited by applicant]
US 5801030A
· McVey et al.
· 1998
[cited by applicant]
US 5858358A
· June et al.
· 1999
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 6180612B1
· Hockensmith et al.
· 2001
[cited by applicant]
US 6309634B1
· Bankiewicz et al.
· 2001
[cited by applicant]
US 6352694B1
· June et al.
· 2002
[cited by applicant]
US 6551786B2
· Manfredi
· 2003
[cited by applicant]
US 6683058B1
· Tuszynski
· 2004
[cited by applicant]
US 6692964B1
· June et al.
· 2004
[cited by applicant]
US 6716662B2
· Akai
· 2004
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6887466B2
· June et al.
· 2005
[cited by applicant]
US 6905680B2
· June et al.
· 2005
[cited by applicant]
US 6905681B1
· June et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 6995011B2
· Itoh et al.
· 2006
[cited by applicant]
US 7067318B2
· June et al.
· 2006
[cited by applicant]
US 7144575B2
· June et al.
· 2006
[cited by applicant]
US 7172869B2
· June et al.
· 2007
[cited by applicant]
US 7175843B2
· June et al.
· 2007
[cited by applicant]
US 7205103B2
· Emerson
· 2007
[cited by applicant]
US 7232566B2
· June et al.
· 2007
[cited by applicant]
US 7572631B2
· Berenson et al.
· 2009
[cited by applicant]
US 8324367B2
· Kaemmerer et al.
· 2012
[cited by applicant]
US 8642660B2
· Goldfarb
· 2014
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8703761B2
· Forster et al.
· 2014
[cited by applicant]
US 8771945B1
· Zhang
· 2014
[cited by applicant]
US 8795965B2
· Zhang
· 2014
[cited by applicant]
US 8865406B2
· Zhang et al.
· 2014
[cited by applicant]
US 8946268B2
· Lau et al.
· 2015
[cited by applicant]
US 9072052B2
· Griffin et al.
· 2015
[cited by applicant]
US 9126985B2
· Kley et al.
· 2015
[cited by applicant]
US 9353051B2
· Byrd et al.
· 2016
[cited by applicant]
US 9410943B2
· Kadoch et al.
· 2016
[cited by applicant]
US 9546206B2
· Ring et al.
· 2017
[cited by applicant]
US 9546296B2
· Wang et al.
· 2017
[cited by applicant]
US 9636323B2
· Lin et al.
· 2017
[cited by applicant]
US 9656959B2
· Ni et al.
· 2017
[cited by applicant]
US 9694084B2
· Bradner et al.
· 2017
[cited by applicant]
US 9708338B2
· Yukimasa et al.
· 2017
[cited by applicant]
US 9708348B2
· Castro et al.
· 2017
[cited by applicant]
US 9932340B2
· Dai et al.
· 2018
[cited by applicant]
US 20020106632A1
· Manfredi
· 2002
[cited by applicant]
US 20050079512A1
· Emerson
· 2005
[cited by examiner]
US 20070105181A1
· Pope
· 2007
[cited by examiner]
US 20120035244A1
· Chinnaiyan
· 2012
[cited by examiner]
US 20160130663A1
· Kohno et al.
· 2016
[cited by applicant]
US 20180140722A1
· Willis et al.
· 2018
[cited by applicant]
US 20180258491A1
· Jagani et al.
· 2018
[cited by applicant]
US 20200069669A1
· Grassian et al.
· 2020
[cited by applicant]
US 20200206344A1
· Kadoch et al.
· 2020
[cited by applicant]
US 20200261434A1
· Choe et al.
· 2020
[cited by applicant]
US 20210171958A1
· Chan et al.
· 2021
[cited by applicant]
US 20210251988A1
· Zhou et al.
· 2021
[cited by applicant]
US 20210260171A1
· Zhou et al.
· 2021
[cited by applicant]
US 20210388040A1
· Kadoch et al.
· 2021
[cited by applicant]
US 20220016083A1
· Centore et al.
· 2022
[cited by applicant]
US 20220396604A1
· Kadoch et al.
· 2022
[cited by applicant]
US 20230079819A1
· Vaswani et al.
· 2023
[cited by applicant]
US 20230129003A1
· Vaswani et al.
· 2023
[cited by applicant]
US 20230149414A1
· Anthony et al.
· 2023
[cited by applicant]
US 20240189318A1
· Huang
· 2024
[cited by applicant]
CN 103038231A
· 2013
[cited by applicant]
CN 104530013A
· 2015
[cited by applicant]
CN 105473141A
· 2016
[cited by applicant]
CN 107531668A
· 2018
[cited by applicant]
EA 202192101A1
· 2021
[cited by applicant]
EP 0172096A1
· 1986
[cited by applicant]
EP 3018123A1
· 2016
[cited by applicant]
JP 2008505963A
· 2008
[cited by applicant]
JP 2011507910A
· 2011
[cited by applicant]
JP 2011528016A
· 2011
[cited by applicant]
JP 2014500303A
· 2014
[cited by applicant]
JP 2016520515A
· 2016
[cited by applicant]
JP 2021512166A
· 2021
[cited by applicant]
JP 2022508155A
· 2022
[cited by applicant]
WO 9410300A1
· 1994
[cited by applicant]
WO WO9530761A2
· 1995
[cited by applicant]
WO WO2000024392A1
· 2000
[cited by applicant]
WO WO0059888A1
· 2000
[cited by applicant]
WO WO0059905A1
· 2000
[cited by applicant]
WO WO2005039643A2
· 2005
[cited by applicant]
WO WO2005112620A2
· 2005
[cited by applicant]
WO WO2006005941A1
· 2006
[cited by applicant]
WO WO2006051063A1
· 2006
[cited by applicant]
WO WO2008022396A1
· 2008
[cited by applicant]
WO WO2009086303A2
· 2009
[cited by applicant]
WO WO2010007046A2
· 2010
[cited by applicant]
WO WO2011115998A2
· 2011
[cited by applicant]
WO WO2012085650A1
· 2012
[cited by applicant]
WO WO2013116663A1
· 2013
[cited by applicant]
WO WO2013116682A1
· 2013
[cited by applicant]
WO WO2014150395A1
· 2014
[cited by applicant]
WO WO2015002230A1
· 2015
[cited by applicant]
WO WO2015005473A1
· 2015
[cited by applicant]
WO WO2015103317A1
· 2015
[cited by applicant]
WO WO2015120320A1
· 2015
[cited by applicant]
WO WO2015121688A1
· 2015
[cited by applicant]
WO WO2016054491A1
· 2016
[cited by applicant]
WO WO2016138114A1
· 2016
[cited by applicant]
WO WO2016160718A1
· 2016
[cited by applicant]
WO WO2016207212A1
· 2016
[cited by applicant]
WO WO2017024318A1
· 2017
[cited by applicant]
WO WO2017060470A1
· 2017
[cited by applicant]
WO WO2017087885A1
· 2017
[cited by applicant]
WO WO2017118734A1
· 2017
[cited by applicant]
WO WO2017150395A1
· 2017
[cited by applicant]
WO WO2017158381A1
· 2017
[cited by applicant]
WO WO2018148443A1
· 2018
[cited by applicant]
WO WO2018160636A1
· 2018
[cited by applicant]
WO WO2018175324A1
· 2018
[cited by applicant]
WO WO2019040098A1
· 2019
[cited by applicant]
WO WO2019138017A1
· 2019
[cited by applicant]
WO WO2019142192A1
· 2019
[cited by applicant]
WO WO2019152437A1
· 2019
[cited by applicant]
WO WO2019152440A1
· 2019
[cited by applicant]
WO WO2019226915A1
· 2019
[cited by applicant]
WO WO2020035779A1
· 2020
[cited by applicant]
WO WO2020081556A2
· 2020
[cited by applicant]
WO WO2020081588A1
· 2020
[cited by applicant]
WO WO2020106915A1
· 2020
[cited by applicant]
WO WO2020127685A1
· 2020
[cited by applicant]
WO WO2020160100A1
· 2020
[cited by applicant]
WO WO2020160180A1
· 2020
[cited by applicant]
WO WO2021081032A1
· 2021
[cited by applicant]
WO WO2021155262A1
· 2021
[cited by applicant]
WO WO2021155264A1
· 2021
[cited by applicant]
WO WO2021155316A1
· 2021
[cited by applicant]
WO WO2021155320A1
· 2021
[cited by applicant]
WO WO2021155321A2
· 2021
[cited by applicant]
WO WO2021183218A1
· 2021
[cited by applicant]
WO WO2021236080A1
· 2021
[cited by applicant]
WO WO2022192621A1
· 2022
[cited by applicant]
WO WO2022198043A1
· 2022
[cited by applicant]
WO WO2023009834A2
· 2023
[cited by applicant]
WO WO2023196560A1
· 2023
[cited by applicant]
WO WO2023196565A1
· 2023
[cited by applicant]
WO WO2023196567A2
· 2023
[cited by applicant]
WO WO2024024428A1
· 2024
[cited by applicant]
WO WO2024031875A1
· 2024
[cited by applicant]
WO WO2024086577A1
· 2024
[cited by applicant]
WO WO2024216136A1
· 2024
[cited by applicant]
WO WO2024216151A1
· 2024
[cited by applicant]
Tuoc et al. (Developmental Cell, May 13, 2013 (May 13, 2013), vol. 25, pp. 256-269). (Year: 2013).
[cited by examiner]
Zong et al. (PNAS, Jul. 28, 2009, vol. 106, No. 30, pp. 12465-12470) (Year: 2009).
[cited by examiner]
Kunderfranco et al. PLos One, May 2010, vol. 5, Issue 5, e10547, pp. 1-17 (Year: 2010).
[cited by examiner]
Shi et al. (Genes & Development, Nov. 27, 2013, vol. 27, pp. 2648-2662) (Year: 2013).
[cited by examiner]
Shen et al. (Cancer Research, Dec. 15, 2008, 68(24), pp. 10154-10162) (Year: 2008).
[cited by examiner]
Gingras et al. (J.Physiology.563.1, 2005, pp. 11-21) (Year: 2005).
[cited by examiner]
Machanick, P. et al.(2011) “MEME-ChIP: motif analysis of large DNA datasets,” Bioinformatics (Oxford, England). 27:1696-1697.
[cited by applicant]
Mackereth, C.D. et al. (2004) “Diversity in structure and function of the Ets family PNT domains,” J Mol Biol. 342:1249-1264.
[cited by applicant]
Madura et al. (1993) “N-recognin/Ubc2 interactions in the N-end rule pathway,” J Biol Chem. 268:12046-12054.
[cited by applicant]
McConnell, H.M. et al. (1992) “The cytosensor microphysiometer: biological applications of silicon technology,” Science. 257:1906-1912.
[cited by applicant]
Mele, M. et al. (2015) “Human genomics. The human transcriptome across tissues and individuals,” Science. 348:660-665.
[cited by applicant]
Mounir, Z. et al. (2016) “ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor,” Elife. 5.
[cited by applicant]
Nagaich, A.K. et al. (2004) “Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling,” Mol Cell. 14:163-174.
[cited by applicant]
Nam et al. (2007) “Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer,” Br J Cancer. 97(12):1690-1695.
[cited by applicant]
Ong, S.E. et al. (2006) “A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC),” Nat Protoc. 1:2650-2660.
[cited by applicant]
Paulo, P. (2012) “FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer,” Genes Chromosomes Cancer. 51:240-249.
[cited by applicant]
Petrovics et al. (2005) “Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome,” Oncogene. 24(23):3847-3852.
[cited by applicant]
Pomerantz, M.M. et al. (2015) “The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis,” Nat Genet. 47:1346-1351.
[cited by applicant]
Prensner, J.R. et al. (2013) “The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex,” Nat Genet. 45:1392-1398.
[cited by applicant]
Quinlan, A.R. et al. (2010) “BEDTools: a flexible suite of utilities for comparing genomic features,” Bioinformatics (Oxford, England). 26:841-842.
[cited by applicant]
Rajput et al. (2007) “Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers,” J Clin Pathol. 60(11):1238-1243.
[cited by applicant]
Rappsilber, J. et al. (2007) “Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips,” Nat Protoc. 2:1896-1906.
[cited by applicant]
Rivas, G. et al. (1993) “New Developments In the Study of Biomolecular Associations Via Sedimentation Equilibrium,” Trends Biochem Sci. 18:284-7.
[cited by applicant]
Roberts, C.W. et al. (2004) “The SWI/SNF complex—chromatin and cancer,” Nat Rev Cancer. 4:133-142.
[cited by applicant]
Scott et al. (1990) “Searching for peptide ligands with an epitope library,” Science. 249(4967):386-390.
[cited by applicant]
Shen, H. et al. (2008) The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 68:10154-10162.
[cited by applicant]
Shi et al. (2013) “Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation,” Genes & Development. 27:2648-2662.
[cited by applicant]
Siegel, R.L. et al. (2015) “Cancer statistics, 2015,” CA Cancer J Clin. 65:5-29.
[cited by applicant]
Sjolander, S. et al. “Integrated fluid handling system for biomolecular interaction analysis,” Anal Chem. 63:2338-2345.
[cited by applicant]
Subramanian, A. et al. (2005) “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proceedings of the National Academy of Sciences USA. 102:15545-15550.
[cited by applicant]
Sun, C. et al. (2008) “TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation,” Oncogene. 27:5348-5353.
[cited by applicant]
Szabo et al. (1995) “Surface plasmon resonance and its use in biomolecular interaction analysis (BIA),” Curr Opin Struc Biol. 5:699-705.
[cited by applicant]
Tomlins, S.A. et ai. (2008) “Role of the TMPRSS2-ERG gene fusion in prostate cancer,” Neoplasia. 10:177-188.
[cited by applicant]
Tomlins, S.A. et al. (2005) “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science. 310:644-648.
[cited by applicant]
Tomlins, S.A. et al. (2006) “TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer,” Cancer Res. 66:3396-3400.
[cited by applicant]
Varambally, S. et al. (2002) “The polycomb group protein EZH2 is involved in progression of prostate cancer,” Nature. 419:624-629.
[cited by applicant]
Verger, A. et al. (2001) “Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation,” J Biol Chem. 276:17181-17189.
[cited by applicant]
Wollenick et al. (2011) “Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling,” Nucleic Acids Research. 40:1928-1943.
[cited by applicant]
Yang, Y.A. et al. (2013) “EZH2, an epigenetic driver of prostate cancer,” Protein Cell. 4:331-341.
[cited by applicant]
Yildirim et al. (2011) “Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells,” Cell. 147:1498-1510.
[cited by applicant]
Yu, J. et al. (2010) “An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression,” Cancer Cell. 17:443-454.
[cited by applicant]
Yu, M. et al. (2012) “Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors,” Mol Cell. 45:330-343.
[cited by applicant]
Tuoc et al. (2013) “Chromatin regulation by BAF170 controls cerebral cortical size and thickness,” Developmental Cell. 25:256-269.
[cited by applicant]
Zervos et al. (1993) “Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites,” Cell. 72:223-232.
[cited by applicant]
Zhang, Y. et al. (2008) “Model-based analysis of ChIP-Seq (MACS),” Genome Biology. 9:R137.
[cited by applicant]
Zong, Y. et al. (2009) “ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells,” Proceedings of the National Academy of Sciences of the Unit…
[cited by applicant]
Zuckermann et al. (1994). “Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library,” J. Med. Chem. 37:2678-2685.
[cited by applicant]
International Search Report with Written Opinion for PCT/US2016/062911 dated Mar. 3, 2017.
[cited by applicant]
International Preliminary Report on Patentability or PCT/US2016/062911 dated May 22, 2018.
[cited by applicant]
Adamo, P. et al. (2016) “The oncogene ERG: a key factor in prostate cancer,” Oncogene. 35:403-414.
[cited by applicant]
Anders, S. et al. (2015) “HTSeq—a Python framework to work with high-throughput sequencing data,” Bioinformatics (Oxford, England). 31:166-169.
[cited by applicant]
Asangani, LA. et al. (2014) “Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer,” Nature. 510:278-282.
[cited by applicant]
Attard et al. (2008) “Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer,” Oncogene 27(3):253-263.
[cited by applicant]
Lupien, M. et al. (2008) “FoxAl translates epigenetic signatures into enhancer-driven lineage-specific transcription,” Cell. 132:958-970.
[cited by applicant]
Basuyaux, J.P. et al.(1997) “The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner,” J Biol Chem. 272:26188-26195.
[cited by applicant]
Bendall, S.C. et al. (2008) “Prevention of amino acid conversion in SILAC experiments with embryonic stem cells,” Mol Cell Proteomics. 7:1587-1597.
[cited by applicant]
Berger, R. et al. (2004) “Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells,” Cancer Res. 64:8867-8875.
[cited by applicant]
Borno, S.T. et al. (2012) “Genome-wide DNA methylation events in 25 TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation,” Cancer Discov. 2:1024-1035.
[cited by applicant]
Camuzeaux et al. (2005) “Imaging Erg and Jun transcription factor interaction in living cells using fluorescence resonance energy transfer analyses,” Biochemical and Biophysical Research Communications. 332:1107-1114.
[cited by applicant]
Cancer Genome Atlas Research, N. (2015) The Molecular Taxonomy of Primary Prostate Cancer, Cell. 163:1011-1025.
[cited by applicant]
Carell et al. (1994) “A Novel Procedure for the Synthesis of Libraries Containing Small Organic Molecules,” Angew. Chem. Int. Ed. Engl. 33:2059-2061.
[cited by applicant]
Carell et al. (1994) “A Solution-Phase Screening Procedure for the Isolation of Active Compounds from a Library of Molecules,” Angew. Chem. Int. Ed. Engl. 33:2061-2064.
[cited by applicant]
Chen, Y. et al. (2013) “ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss,” Nat Med. 19:1023-1029.
[cited by applicant]
Chng, K.R. et al.(2012) “A transcriptional repressor co-regulatory network governing androgen response in prostate cancers,” EMBO J. 31:2810-2823.
[cited by applicant]
Cho et al. (1993) “An unnatural biopolymer,” Science. 261:1303-1305.
[cited by applicant]
Clark, J. et al. (2008) “Complex patterns of ETS gene alteration arise during cancer development in the human prostate,” Oncogene. 27:1993-2003.
[cited by applicant]
Clark, J.P. et al. (2009) “ETS gene fusions in prostate cancer,” Nat Rev Urol. 6:429-439.
[cited by applicant]
Cull et al. (1992) “Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor,” Proc Natl Acad Sci U S A. 89(5):1865-1869.
[cited by applicant]
Cwirla et al. (1990) “Peptides on phage: A vast library of peptides for identifying ligands,” Proc. Natl. Acad. Sci. USA. 87:6378-6382.
[cited by applicant]
Delattre, O. et al. (1992) “Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature. 359:162-165.
[cited by applicant]
Demichelis et al. (2007) “TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort,” Oncogene. 26(31):4596-4599.
[cited by applicant]
Devlin (1990) “Random peptide libraries: a source of specific protein binding molecules,” Science. 249:404-406.
[cited by applicant]
DeWitt et al. (1993) ““Diversomers”: an approach to nonpeptide, nonoligomeric chemical diversity,” Proc. Natl. Acad. Sci. U.S.A. 90(15):6909-6913.
[cited by applicant]
Dobin, A. et al. (2013) “STAR: ultrafast universal RNA-seq aligner,” Bioinformatics (Oxford, England). 29:15-21.
[cited by applicant]
Donaldson, L.W. et al. (1996) “Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif,” EMBO J. 15:125-134.
[cited by applicant]
Erb et al. (1994) “Recursive deconvolution of combinatorial chemical libraries,” Proc. Natl. Acad. Sci. USA 91:11422-11426.
[cited by applicant]
Felicia et al. (1991) “Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector,” J Mol Biol. 222:301-310.
[cited by applicant]
Feng, J. et al. (2012) “GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data,” Bioinformatics (Oxford, England). 28:2782-2788.
[cited by applicant]
Fodor et al. (1993) “Multiplexed biochemical assays with biological chips,” Nature. 364(6437):555-556.
[cited by applicant]
Gallop et al. (1994) “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries,” J Med Chem. 37:1233-51.
[cited by applicant]
Gene Ontology Consortium. (2015) “Gene Ontology Consortium: going forward,” Nucleic Acids Res. 43:1049-1056.
[cited by applicant]
Hage, D.S. et al. (1997) “Recent advances in chromatographic and electrophoretic methods for the study of drug-protein interactions,” J Chromatogr B Biomed Sci Appl. 699:499-525.
[cited by applicant]
Heegaard et al. (1998) “Capillary electrophoresis for the study of affinity interactions,” J Mol Recognit. 11:141-8.
[cited by applicant]
Helgeson, B.E. et al. (2008) “Characterization of TMPRSS2:ETV5 and SLC45A3:E11/5 gene fusions in prostate cancer,” Cancer Res. 68:73-80.
[cited by applicant]
Ho, L. (2009) “An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network,” Proceedings of the National Academy of Sciences of the United State…
[cited by applicant]
Houghten (1992) “The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides,” Biotechniques. 13:412-421.
[cited by applicant]
Ichikawa, H. et al. (1994) “An RNA-binding protein 25 gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation,” Cancer Res. 54:2865-2868.
[cited by applicant]
Kadoch, C. et al. (2013) “Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy,” Nat Genet. 45:592-601.
[cited by applicant]
Kadoch, C. et al. (2015) “Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics,” Sci Adv. 1:e1500447.
[cited by applicant]
Karim et al. (1990) “The ETS-domain a new DNA-binding motif that recognizes a purine-rich core DNA sequence,” Genes & Development. 4:1451-1453.
[cited by applicant]
Klezovitch, O. et al.(2008) “A causal role for ERG in neoplastic transformation of prostate epithelium,” Proceedings of the National Academy of Sciences of the United States of America. 105:2105-2110.
[cited by applicant]
Kumar-Sinha, C. et al. (2008) “Recurrent gene fusions in prostate cancer,” Nat Rev Cancer. 8:497-511.
[cited by applicant]
Kunderfranco, P. et al. (2010) “ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer,” PLoS One. 5:e10547.
[cited by applicant]
Lam (1991) “A new type of synthetic peptide library for identifying ligand-binding activity,” Nature. 354:82-84.
[cited by applicant]
Lam (1997) “Application of combinatorial library methods in cancer research and drug discovery,” Anticancer Drug Des. 12(3):145-67.
[cited by applicant]
Langmead, B. et al. (2012) “Fast gapped-read alignment with Bowtie 2,” Nature Methods. 9:357-359.
[cited by applicant]
Link, K.A. et al. (2008) “Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity,” Cancer Res. 68:4551-4558.
[cited by applicant]
Love, M.I. et al. (2014) “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome Biology. 15:550.
[cited by applicant]
“FLI1 gene”, MedlinePlus, published May 1, 2012, <https://medlineplus.gov/genetics/> (3 pages).
[cited by applicant]
Advani et al., “A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.” Leukemia research 34.12 (2010): 1622-1626.
[cited by applicant]
Alazawi, “Foghorn Therapeutics,” Blackseed Bio, last updated Mar. 4, 2022, retrieved Jul. 24, 2023, from <https://blackseedbio.com/reports/fhtx#pipeline> (26 pages).
[cited by applicant]
Boulay et al., “Cancer-specific retargeting of BAF complexes by a prion-like domain.” Cell 171.1 (2017): 163-178.
[cited by applicant]
CAS RN: 1223164-86-0; STN entry date: May 14, 2010; N-[2-[[4-(3-Fluoro-4-methoxyphenyl)-2- thiazolyl]amino]-2-oxoethyl]-2-methyl-3-furancarboxamide.
[cited by applicant]
CAS RN: 1300403-14-8; STN entry date May 25, 2011; 5-Methyl-N-[2-oxo-2-[ (5-phenyl-2-pyridinyl)amino]ethyl]-2-thiophenecarboxamide.
[cited by applicant]
CAS RN: 924410-17-3; STN entry date: Mar. 2, 2007; 5-Methyl-N-[2-oxo-2-[ (4-phenyl-2-thiazolyl)amino]ethyl]-2-thiophenecarboxamide.
[cited by applicant]
CAS RN: 924420-04-2; STN entry date: Mar. 2, 2007; 5-Methyl-N-[2-oxo-2-[[4-(4-pyridinyl)-2-thiazolyl]amino]ethyl]-2-thiophenecarboxamide.
[cited by applicant]
Centore et al., “Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers,” Poster Presentations—Proffered abstracts, Cancer Research 81(13_Supplement): 1224.
[cited by applicant]
Chandler et al., “ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF,” Mol Cell Biol. 33(2):265-80.
[cited by applicant]
Chattopadhyay et al., “Uveal melanoma: From diagnosis to treatment and the science in between,” Cancer. 122(15):2299-2312.
[cited by applicant]
Coban et al., “Synthesis, biological activity screening and molecular modeling study of acylaminoacetamide derivatives,” Med Chem Res. 24(10):3710-29.
[cited by applicant]
Danziger et al., “Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces”, Proc R Soc Lond B Biol Sci. 236(1283): 101-113.
[cited by applicant]
Database Registry, RN 1004932-80-2, entered Feb. 21, 2008.
[cited by applicant]
Database Registry, RN 1175782-23-6, entered Aug. 26, 2009.
[cited by applicant]
Database Registry, RN 1315743-98-6, entered Aug. 11, 2011.
[cited by applicant]
Database Registry, RN 1323331-37-8, entered Aug. 25, 2011.
[cited by applicant]
Database Registry, RN 1323542-96-6, entered Aug. 26, 2011.
[cited by applicant]
Database Registry, RN 1324163-01-0, entered Aug. 28, 2011.
[cited by applicant]
Database Registry, RN 1327304-26-6, entered Sep. 2, 2011.
[cited by applicant]
Database Registry, RN 878254-76-3, entered Mar. 28, 2006.
[cited by applicant]
Décor et al., “Design, synthesis and biological evaluation of novel aminothiazoles as antiviral compounds acting against human rhinovirus,” Bioorg Med Chem Lett. 23(13):3841-7 (2013).
[cited by applicant]
Dominguez et al. “Beyond editing: Repurposing CRISPR-Cas9 for Precision Genome Regulation and Interrogation,” available in PMC Jun. 27, 2016, published in final edited form as: Nat Rev Mol Cell Biol. 17(1):5-15 (Jan. 20…
[cited by applicant]
Extended European Search Report for EP Application No. 19748410.8 dated Sep. 24, 2021.
[cited by applicant]
Extended European Search Report for EP Application No. 19887386.1 dated Dec. 5, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 20749261.2 dated Oct. 18, 2022.
[cited by applicant]
Extended European Search Report for EP Application No. 21748261.1 dated Jan. 29, 2024.
[cited by applicant]
Fadul et al., “EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma,” Genes Cancer 6(3-4):129-43 (2015).
[cited by applicant]
Fathi et al., “Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia,” Am J Hematol. 96(6):735-46 (Jun. 1, 2021).
[cited by applicant]
Gaj et al. “ZFN, TALEN and CRISPR/Cas-based Methods for Genome Engineering,” available in PMC Jul. 1, 2014, published in final edited form as: Trends Biotechnol. 31(7):397-405 (Jul. 2013).
[cited by applicant]
Godwin et al., “Gemtuzumab ozogamicin in acute myeloid leukemia,” Leukemia 31(9):1855-68 (Sep. 2017).
[cited by applicant]
Grohar et al., “Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells,” Neoplasia 13(2):145-53 (Feb. 2011).
[cited by applicant]
Herrero-Martin et al., “Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target,” Br J Cancer 101(1):80-90 (Jul. 7, 2009).
[cited by applicant]
Hohmann et al., “Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition,” Nat Chem Biol. 12(9): 672-679 (Sep. 2016) (12 pages).
[cited by applicant]
Hosler et al. Chapter 8: 199-229, 50 pages (2014).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US19/15722 dated Aug. 4, 2020.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US19/56312 dated Apr. 14, 2021.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US20/33829 dated Nov. 17, 2022.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US22/19506 dated Sep. 12, 2023.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US22/20943 dated Sep. 12, 2023.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US18/000339 dated Jan. 28, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/15722 dated May 31, 2019.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/56312 dated Jan. 14, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/56365 dated Jan. 30, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/62525 dated Feb. 18, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/15605 dated Jun. 16, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/15723 dated Jul. 2, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US20/33829 dated Aug. 17, 2020.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/15876 dated Apr. 7, 2021.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/15878 dated Jun. 4, 2021.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/19506 dated Jun. 7, 2022.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US22/20943 dated Jun. 14, 2022.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/17821 dated Jun. 30, 2023.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/17829 dated Aug. 23, 2023.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/17839 dated Sep. 6, 2023.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/77088 dated Mar. 4, 2024.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US24/24407 dated Jun. 24, 2024.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US24/24428 dated Jul. 16, 2024.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US24/31875 dated Oct. 18, 2024.
[cited by applicant]
Jones et al., “A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo,” J Med Chem. 51(8):2350-3 (Apr. 24, 2008).
[cited by applicant]
Kadoch et al., “Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma,” available in PMC May 16, 2013, published in final edited form as: Cell. 153(1):71-85 (2013).
[cited by applicant]
Kedage et al., “An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer,” Cell Rep. 17(5):1289-301 (Oct. 25, 2016).
[cited by applicant]
McBride et al., “Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities,” J Pathol. 244(5): 638-649 (Apr. 2018).
[cited by applicant]
Michel et al., “Abstract PR15: BRD9 defines a novel mammalian SWI/SNF (BAF) complex configuration which supports proliferation in AML,” Clin Cancer Res. 23(24_Suppl) Abstract PR15 (2017).
[cited by applicant]
Mill et al., “RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1,” Blood 134(1):59-73 (Jul. 4, 2019).
[cited by applicant]
Office Action for Chinese Patent Application No. 201980023925.9 dated Apr. 20, 2022.
[cited by applicant]
Papillon et al., “Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers,” J Med Chem. 61(22):10155-72 (Nov. 2018).
[cited by applicant]
Pescatore et al., “Optimization of a series of potent and selective ketone histone deacetylase inhibitors,” Bioorg Med Chem Lett. 18(20):5528-32 (Oct. 15, 2008).
[cited by applicant]
PubChem CID 117640569, “N-[2-[[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]amino]-2-oxoethyl]-1,3-thiazole-5-carboxamide,” https://pubchem.ncbi.nlm.nih.gov/compound/117640569, created Feb. 23, 2016 (9 pages).
[cited by applicant]
PubChem CID 56442706, “1-(4-Methoxyphenyl)-N-[2-oxo-2-[4-(1,2,4-triazol-1-yl)anilino]ethyl]pyrazole-3-carboxamide,” https://pubchem.ncbi.nlm.nih.gov/compound/56442706, created Jan. 25, 2012 (8pages).
[cited by applicant]
PubChem CID 91946137, “N-[2-[(1-Ethylpyrazol-3-yl}amino]-2-oxoethyl]-1-methylpyrazole-3-carboxamide,” https://pubchem.ncbi.nlm.nih.gov/compound/91946137, created Oct. 22, 2015 (8pages).
[cited by applicant]
PubChem Compound Summary for CID 155037309, dated Dec. 19, 2020 (9 pages).
[cited by applicant]
PubChem Compound Summary for CID No. 136572628, “4-Chloro-N-[2-(cyclopentylamino)-2-oxoethyl]-5-nitro-1H-pyrazole-3-carboxamide,” created Jan. 24, 2019, <https://pubchem.ncbi.nlm.nih.gov/compound/136572628>, (7 pages).
[cited by applicant]
PubChem Compound Summary for CID No. 49726797, “N-Methyl-N-(2-oxo-2-((4-(pyridin-3-yl)thiazol-2-yl)amino)ethyl)-1H-indole-3-carboxamide,” created Nov. 27, 2010, <https://pubchem.ncbi.nlm.nih.gov/compound/497267 7>, (8 p…
[cited by applicant]
PubChem Compound Summary for CID No. 91945707, “N-[2-[(4,5-Dimethyl-1,3-thiazol-2-yl)amino]-2-oxoethyl]-1-methylpyrazole-3-carboxamide,” created Oct. 22, 2015 <https://pubchem.ncbi.nlm.nih.gov/compound/91945707>, (8 pag…
[cited by applicant]
PubChem Compound Summary for PubChem CID 49726798, “N-(2-((4-(Furan-2-yl)thiazol-2-yl)amino)-2-oxoethyl)-N-methyl-1H-indole-3-carboxamide,” created Nov. 27, 2010 <https://pubchem.ncbi.nih.gov/compound/49726798> (8 pages…
[cited by applicant]
PubChem Compound Summary for SID 172131678, dated Dec. 9, 2014 (8 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 108452511,” <https://pubchem.ncbi.nlm.nih.gov/compound/108452511>, created Jan. 15, 2016, retrieved Jan. 4, 2021 (7 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 2955118,” <https://pubchem.ncbi.nlm.nih.gov/compound/2955118>, created Jul. 29, 2005, retrieved Mar. 22, 2017 (13 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 7325930,” <https://pubchem.ncbi.nlm.nih.gov/compound/7325930>, created Jul. 29, 2006, retrieved Mar. 22, 2017 (11 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 970466,” <https://pubchem.ncbi.nlm.nih.gov/compound/970466>, created Jul. 9, 2005, retrieved Mar. 22, 2017 (11 pages).
[cited by applicant]
Rago et al., “Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia,” Mol Cancer Res. 20(3):361-72 (Mar. 1, 2022).
[cited by applicant]
Ramos et al., “Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia,” J Clin Med. 4(4):665-95 (Apr. 2015).
[cited by applicant]
Riggi et al., “EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma,” Cancer Cell 26(5):668-81 (Nov. 10, 2014) (28 pages).
[cited by applicant]
Sankar et al., “Promiscuous partnerships in Ewing's sarcoma,” Cancer Genet. 204(7):351-65 (Jul. 2011) (28 pages).
[cited by applicant]
Schiefer et al., “Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors,” J Med Chem. 56(15):6054-68 (Feb. 7, 2013).
[cited by applicant]
Simone, Part XIV: Oncology: Introduction, Textbook of Medicine, Bennett et al., 20(1), 1004-1010 (1997).
[cited by applicant]
Spickler et al., “Phosphatidylinositol 4-kinase III beta is essential for replication of human rhinovirus and its inhibition causes a lethal phenotype in vivo,” Antimicrob Agents Chemother. 57(7):3358-68 (Jul. 2013).
[cited by applicant]
STN Registry Database, CAS RN 858073-83-3, Albany Molecular Research, Inc., entered Aug. 3, 2005.
[cited by applicant]
STN Registry Database, RN 1010893-05-6, entered Mar. 30, 2008.
[cited by applicant]
STN Registry Database, RN 1049271-26-2, entered Sep. 14, 2008.
[cited by applicant]
STN Registry Database, RN 1081662-32-9, entered Dec. 8, 2008.
[cited by applicant]
STN Registry Database, RN 1209112-42-4, entered Mar. 12, 2010.
[cited by applicant]
STN Registry Database, RN 1246047-75-5, entered Oct. 12, 2010.
[cited by applicant]
STN Registry Database, RN 1308280-67-2, entered Jun. 9, 2011.
[cited by applicant]
STN Registry Database, RN 1351682-19-3, entered Dec. 22, 2011.
[cited by applicant]
STN Registry Database, RN 1401558-47-1, entered Oct. 22, 2012.
[cited by applicant]
STN Registry Database, RN 1455783-72-8, entered Oct. 6, 2013.
[cited by applicant]
STN Registry Database, RN 1576383-94-2, entered Mar. 31, 2014.
[cited by applicant]
STN Registry Database, RN 1586193-45-4, entered Apr. 17, 2014.
[cited by applicant]
STN Registry Database, RN 1827759-12-5, entered Dec. 13, 2015.
[cited by applicant]
STN Registry Database, RN 1831899-24-1, entered Dec. 17, 2015.
[cited by applicant]
STN Registry Database, RN 1839545-15-1, entered Dec. 31, 2015.
[cited by applicant]
STN Registry Database, RN 923768-18-7, entered Feb. 28, 2007.
[cited by applicant]
STN Registry Database, RN 923809-79-4, entered Feb. 28, 2007.
[cited by applicant]
STN Registry Database, RN 931893-54-8, entered Apr. 23, 2007.
[cited by applicant]
STN Registry Database, RN 932130-00-2, entered Apr. 24, 2007.
[cited by applicant]
STN Registry Database, RN 938283-11-5, entered Jun. 22, 2007.
[cited by applicant]
Takigami et al., “Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model,” Int J Cancer 128(1):216-26 (2011).
[cited by applicant]
Tikdari et al., “Reaction of 2-Aminothiazoles with 5-Oxazolones,” ChemInform. 18(47): Abstract 199 (1987).
[cited by applicant]
Tikdari et al., “Reaction of 2-Aminothiazoles with 5-Oxazolones,” Indian Journal of Chemistry 26B:478-9 (May 1987).
[cited by applicant]
Triandafillidi et al., “tert-Butyl ester or benzylamide of the dipeptide Pro-Gly as organocatalysts for the asymmetric aldol reaction,” Tetrahedron 71:932-40 (Feb. 2015).
[cited by applicant]
Tsai et al. “Dimeric CRISPR RNA-guided Fokl Nucleases for Highly Specific Genome Editing,” available in PMC Dec. 1, 2014, published in final edited form as: Nat Biotechnol. 32(6):569-576 (Jun. 2014).
[cited by applicant]
Vachtenheim et al., “SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells,” Biochemical and Biophysical Research Communications. 392(3):…
[cited by applicant]
Vela et al., “Discovery of Enhancers of the Secretion of Leukemia Inhibitory Factor for the Treatment of Multiple Sclerosis,” J Biomol Screen. 21(5):437-45 (2016).
[cited by applicant]
Wahedy et al., “Facile Synthesis and In-Vitro Antimicrobial Activity of Some Novel 2-Hetroamido-5-Amino Benzimidazoles,” Am J PharmTech Res. 3(2):868-82 (2013).
[cited by applicant]
Wu et al., “Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells,” Oncotarget 7(19):27158-75 (2016).
[cited by applicant]
Zhang et al., “Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase,” Eur J Med Chem. 58:624-39 (2012).
[cited by applicant]
Zvarec et al., “5-Benzylidenerhodanine and 5-benzylidene-2-4-thiazolidinedione based antibacterials,” Bioorg Med Chem Lett. 22(8):2720-2 (2012).
[cited by applicant]
Cited By (4)